StockData
Longeveron Inc. logo

Longeveron Inc. (LGVN) stock

LGVNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 5/30
$1.92−0.19 (-9.00%)

Close on Nov 18, 2026Market cap $61.21MP/E –Yield –

Longeveron operating margin

Operating margin is operating income as a percentage of revenue.

Longeveron's operating margin for the twelve months ending Jun 30, 2026 was -1992.8%. For fiscal 2025 it was -1942.2%, against -690.7% the year before. The highest annual figure on record is -67.1% in fiscal 2020.

Annual operating margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 2025-1942.2%−1251.5
FY2024Dec 31, 2024-690.7%+2275.3
FY2023Dec 31, 2023-2966.0%−1489.5
FY2022Dec 31, 2022-1476.5%−139.9
FY2021Dec 31, 2021-1336.6%−1269.5
FY2020Dec 31, 2020-67.1%–

Quarterly operating margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q2 FY2026Jun 30, 2026-2150.2%−442.3
Q1 FY2026Mar 31, 2026-1199.7%+160.1
Q4 FY2025Dec 31, 2025-1479.2%−769.2
Q3 FY2025Sep 30, 2025-5335.8%−4734.3
Q2 FY2025Jun 30, 2025-1707.9%−960.0
Q1 FY2025Mar 31, 2025-1359.8%−613.5
Q4 FY2024Dec 31, 2024-710.0%+7925.0
Q3 FY2024Sep 30, 2024-601.4%+2839.2
Q2 FY2024Jun 30, 2024-747.9%+1884.4
Q1 FY2024Mar 31, 2024-746.4%+944.0
Q4 FY2023Dec 31, 2023-8634.9%−7729.1
Q3 FY2023Sep 30, 2023-3440.7%−2523.4
Q2 FY2023Jun 30, 2023-2632.3%−703.1
Q1 FY2023Mar 31, 2023-1690.3%+423.9
Q2 FY2022Jun 30, 2022-905.8%+129.4
Q1 FY2022Mar 31, 2022-917.3%+2.4
Q4 FY2021Dec 31, 2021-1929.2%−1812.0
Q3 FY2021Sep 30, 2021-2114.2%−2062.9
Q2 FY2021Jun 30, 2021-1035.2%−895.2
Q1 FY2021Mar 31, 2021-919.7%−907.2
Q4 FY2020Dec 31, 2020-117.2%–
Q3 FY2020Sep 30, 2020-51.4%–
Q2 FY2020Jun 30, 2020-140.0%–
Q1 FY2020Mar 31, 2020-12.5%–

More Longeveron figures

See a number that looks wrong?